KDR and triple-negative breast carcinoma: For example, pyrimidines act as selective dual inhibitors of c-Met and VEGFR-2 [10], dual ERα/VEGFR-2 ligands with anti-breast cancer activity [11], and selective inhibitors against triple-negative breast cancer cell line MDA-MB-468 [12], and they have antiproliferative activity and EGFR and ARO inhibitory activity [13].